Elizabeth Jungman

Elizabeth Jungman

  • Director
  • Public Health,
  • The Pew Charitable Trusts


Elizabeth Jungman directs Pew’s work on public health, overseeing initiatives related to antibiotics and innovation, drug safety, and prescription drug abuse.

Before joining Pew, she served as a senior health policy adviser with the U.S. Senate Committee on Health, Education, Labor, and Pensions, where she played a key role in drafting and negotiating the Food and Drug Administration Safety and Innovation Act of 2012, the FDA provisions in the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013, and the Drug Quality and Security Act of 2013, which included drug compounding and supply chain security measures.

Before moving to the Hill, Jungman was in private legal practice, counseling clients on a broad range of FDA regulatory matters and other health care issues related to the human pharmaceutical industry. She serves on FDA’s Pharmacy Compounding Advisory Committee and represents Pew as a member of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria. She has an undergraduate biology degree from Harvard College, a Juris Doctor from Georgetown University, and a master’s degree in public health from Johns Hopkins University.

Recent Work

View All
  • FDA Proposals for Compounded Drugs Draw Broad Support

    The U.S. Food and Drug Administration (FDA) issued three draft guidance documents in April on implementation of the Drug Quality and Security Act (DQSA), a 2013 law governing the production of compounded drugs—medications made by pharmacies instead of drug manufacturers. Read More

  • Pew Urges Senate to Protect Patient Safeguards in Compounding Law

    The Pew Charitable Trusts, together with the American Public Health Association, the Biotechnology Innovation Organization, the Generic Pharmaceutical Association, the Pharmaceutical Research and Manufacturers of America, and Trust for America’s Health, sent a letter to the chair and ranking member of the U.S. Senate Appropriations Subcommittee on Agriculture, Rural Development, Food and... Read More

  • Drug Compounding: Steps to Boost Public Safety

    Compounded drugs—medications mixed or altered by pharmacists—are a critical component of health care, but they can carry serious, yet little-known, risks to patient safety. In light of Patient Safety Awareness Week from March 13 to 19, now is a good time for the public and health care professionals to understand the facts and concerns behind drug compounding.  Read More

Media Contact

Tami Holzman

Officer, Communications